Inhibition of Novel β Coronavirus Replication by a Combination of Interferon-α2b and Ribavirin

Overview

Journal Sci Rep

Specialty Science

Date 2013 Apr 19

PMID 23594967

Citations 193

Authors

Darryl Falzarano

Emmie de Wit

Cynthia Martellaro

Julie Callison

Vincent J Munster

Heinz Feldmann

Affiliations

Soon will be listed here.

Abstract

The identification of a novel β coronavirus, nCoV, as the causative agent of severe respiratory illness in humans originating in Saudi Arabia, Qatar and Jordan has raised concerns about the possibility of a coronavirus pandemic similar to that of SARS-CoV. As a definitive treatment regimen has never been thoroughly evaluated for coronavirus infections, there is an urgent need to rapidly identify potential therapeutics to address future cases of nCoV. To determine an intervention strategy, the effect of interferon-α2b and ribavirin on nCoV isolate hCoV-EMC/2012 replication in Vero and LLC-MK2 cells was evaluated. hCoV-EMC/2012 was sensitive to both interferon-α2b and ribavirin alone in Vero and LLC-MK2 cells, but only at relatively high concentrations; however, when combined, lower concentrations of interferon-α2b and ribavirin achieved comparable endpoints. Thus, a combination of interferon-α2b and ribavirin, which are already commonly used in the clinic, may be useful for patient management in the event of future nCoV infections.

Citing Articles

Harnessing the power of IFN for therapeutic approaches to COVID-19.

Viox E, Bosinger S, Douek D, Schreiber G, Paiardini M J Virol. 2024; 98(5):e0120423.

PMID: 38651899 PMC: 11092331. DOI: 10.1128/jvi.01204-23.

A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.

Sharun K, Tiwari R, Yatoo M, Natesan S, Megawati D, Singh K Narra J. 2024; 2(3):e92.

PMID: 38449903 PMC: 10914132. DOI: 10.52225/narra.v2i3.92.

An approach to develop potential therapies against Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

Biswas S, Mita M, Afrose S, Hasan M, Shimu M, Zaman S Heliyon. 2024; 10(4):e25837.

PMID: 38379969 PMC: 10877303. DOI: 10.1016/j.heliyon.2024.e25837.

Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.

Jagannathan P, Chew K, Giganti M, Hughes M, Moser C, Main M EClinicalMedicine. 2023; 65:102250.

PMID: 37855026 PMC: 10579289. DOI: 10.1016/j.eclinm.2023.102250.

Therapeutic Management with Repurposing Approaches: A Mystery During COVID-19 Outbreak.

Chaudhury S, Kaur P, Gupta D, Anand P, Chaudhary M, Tiwari S Curr Mol Med. 2023; 24(6):712-733.

PMID: 37312440 DOI: 10.2174/1566524023666230613141746.

References

Booth C, Matukas L, Tomlinson G, Rachlis A, Rose D, Dwosh H . Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289(21):2801-9. DOI: 10.1001/jama.289.21.JOC30885. View

Sung J, Wu A, Joynt G, Yuen K, Lee N, Chan P . Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax. 2004; 59(5):414-20. PMC: 1746995. DOI: 10.1136/thx.2003.014076. View

Wills R . Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990; 19(5):390-9. DOI: 10.2165/00003088-199019050-00003. View

Pearlman B . Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis. 2012; 12(9):717-28. DOI: 10.1016/S1473-3099(12)70060-9. View

Kumaki Y, Day C, Bailey K, Wandersee M, Wong M, Madsen J . Induction of interferon-gamma-inducible protein 10 by SARS-CoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice. Antivir Chem Chemother. 2010; 20(4):169-77. DOI: 10.3851/IMP1477. View

Wong S, Yuen K . The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother. 2008; 62(3):437-41. PMC: 7109825. DOI: 10.1093/jac/dkn243. View

Shah N, Sunderland A, Grdzelishvili V . Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin. PLoS One. 2010; 5(6):e11265. PMC: 2889835. DOI: 10.1371/journal.pone.0011265. View

Hausfater P, Cacoub P, Assogba U, Lebon P, Piette J . Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis. Nephron. 2002; 91(4):627-30. DOI: 10.1159/000065023. View

Morgenstern B, Michaelis M, Baer P, Doerr H, Cinatl Jr J . Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2004; 326(4):905-8. PMC: 7092851. DOI: 10.1016/j.bbrc.2004.11.128. View

10.

Brochot E, Castelain S, Duverlie G, Capron D, Nguyen-Khac E, Francois C . Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antivir Ther. 2010; 15(5):687-95. DOI: 10.3851/IMP1609. View

11.

Tsang K, Ho P, Ooi G, Yee W, Wang T, Chan-Yeung M . A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003; 348(20):1977-85. DOI: 10.1056/NEJMoa030666. View

12.

Loutfy M, Blatt L, Siminovitch K, Ward S, Wolff B, Lho H . Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003; 290(24):3222-8. DOI: 10.1001/jama.290.24.3222. View

13.

Paeshuyse J, Dallmeier K, Neyts J . Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol. 2012; 1(6):590-8. DOI: 10.1016/j.coviro.2011.10.030. View

14.

Chan K, Lai S, Chu C, Tsui E, Tam C, Wong M . Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003; 9(6):399-406. View

15.

Wise J . Patient dies from novel coronavirus in UK. BMJ. 2013; 346:f1133. DOI: 10.1136/bmj.f1133. View

16.

Kumaki Y, Day C, Wandersee M, Schow B, Madsen J, Grant D . Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Biochem Biophys Res Commun. 2008; 371(1):110-3. PMC: 2441846. DOI: 10.1016/j.bbrc.2008.04.006. View

17.

Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt G . A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003; 348(20):1986-94. DOI: 10.1056/NEJMoa030685. View

18.

Peiris J, Chu C, Cheng V, Chan K, Hung I, Poon L . Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361(9371):1767-72. PMC: 7112410. DOI: 10.1016/s0140-6736(03)13412-5. View

19.

Groneberg D, Poutanen S, Low D, Lode H, Welte T, Zabel P . Treatment and vaccines for severe acute respiratory syndrome. Lancet Infect Dis. 2005; 5(3):147-55. PMC: 7106466. DOI: 10.1016/S1473-3099(05)01307-1. View

20.

. Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveill. 2013; 18(11):20427. DOI: 10.2807/ese.18.11.20427-en. View